Aytu Biopharma, Inc.
AYTU
$1.27
$0.010.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -23.62% | -26.93% | -32.46% | -18.08% | -14.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.62% | -26.93% | -32.46% | -18.08% | -14.73% |
| Cost of Revenue | -30.30% | -43.28% | -49.56% | -36.60% | -30.51% |
| Gross Profit | -20.10% | -17.39% | -22.00% | -4.95% | -3.13% |
| SG&A Expenses | -22.83% | -32.53% | -35.10% | -33.92% | -20.18% |
| Depreciation & Amortization | 5.03% | -1.55% | -7.10% | -11.27% | -18.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.27% | -34.64% | -38.80% | -35.79% | -27.51% |
| Operating Income | 15.72% | 99.84% | 94.00% | 111.83% | 82.78% |
| Income Before Tax | 70.22% | 84.61% | 25.88% | 63.59% | 79.51% |
| Income Tax Expenses | 36.15% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.20% | 75.69% | 15.79% | 60.25% | 78.49% |
| Earnings from Discontinued Operations | 133.92% | 29.21% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.87% | 74.46% | 7.08% | 55.40% | 76.56% |
| EBIT | 15.72% | 99.84% | 94.00% | 111.83% | 82.78% |
| EBITDA | -17.44% | 321.66% | 292.29% | 168.77% | 124.74% |
| EPS Basic | 75.98% | 81.48% | 42.19% | 80.20% | 91.44% |
| Normalized Basic EPS | 107.01% | 104.23% | 57.18% | 81.79% | 74.44% |
| EPS Diluted | 56.43% | 74.94% | 42.15% | 80.18% | 91.44% |
| Normalized Diluted EPS | 100.68% | 101.59% | 57.18% | 81.79% | 74.44% |
| Average Basic Shares Outstanding | 23.76% | 38.12% | 64.11% | 85.40% | 111.78% |
| Average Diluted Shares Outstanding | 52.29% | 56.53% | 64.11% | 85.40% | 111.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
